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Introduction
Thrombosis remains the commonest cause of death
(including premature death) in developed countries, and
is a growing epidemic in developing countries because of
increasing prevalence of smoking, obesity, hypertension
and type 2 diabetes.
Primary and secondary prevention of thrombosis is
therefore an important part of public health, and primary
and secondary healthcare. In addition to public and
individual education (and management) of smoking,
exercise, obesity, hypertension, diabetes and hypercholes-
terolaemia) antithrombotic drugs have an important
role. In recent years, many randomized controlled trials
have not only clarified the antithrombotic benefits
(and bleeding risks) of traditional antiplatelets (aspirin),
anticoagulants (unfractionated heparin, warfarin) and
thrombolytics (streptokinase) but have also investigated
the role of newer antithrombotics. Evidence-based guide-
lines on antithrombotic therapy are now reviewed every
few years, to keep pace with advances in knowledge
from new trials, and epidemiological studies [1–3]. This
review considers the nature of thrombosis, antithrombotic
therapies, the endpoints used in such studies, and the
potential use of blood thrombotic markers in predicting
persons at increased thrombotic risk.
Thrombosis: haemostasis in the wrong place
There is increasing evidence that thrombosis is ‘haemo-
stasis in the wrong place’ (Table 1). Haemostasis is the
continuous process through which bleeding following
injury to small blood vessels (e.g. mechanical stresses
of daily life, trauma, surgical and medical procedures) is
arrested. Vascular injury exposes flowing blood to
subendothelial collagen and to substances released from
damaged cells such as adenosine diphosphate (ADP).
These activate circulating platelets, which adhere to
the injured vessel wall and aggregate forming an initial,
platelet-rich haemostatic plug which arrests bleeding
within a few minutes (primary haemostasis). Simul-
taneously, blood coagulation factors are activated,
primarily through exposure of flowing blood to tissue
factor, which activates coagulation factor VII. Coagulation
factors interact on platelet and other cell surfaces, generat-
ing thrombin from prothrombin. Thrombin converts
circulating fibrinogen to fibrin, which stabilizes the
initial platelet plug and prevents secondary haemorrhage
(secondary haemostasis). Thrombin also activates platelets;
generates further coagulation by activating factors V and
VIII; activates factor XIII which cross-links fibrin, which
increases its resistance to lysis by the endogenous fibrino-
lytic system; and inhibits fibrinolysis through the thrombin
activated fibrinolytic inhibitor (TAFI). The fibrinolytic
system digests the fibrin haemostatic plug over several
days, in parallel with tissue repair. Tissue-type plasmino-
gen activator activates plasminogen to plasmin, which
degrades fibrin to fibrin degradation products (FDP), such
as fibrin D-Dimer.
Excessive generalized bleeding can arise from fragile
blood vessels (e.g. scurvy), low platelet count, low con-
centrations of platelet cofactors (most commonly von
Willebrand’s disease in which plasma von Willebrand
factor (vWF) levels are low, reducing platelet adhesion and
aggregation), low concentrations of coagulation factors
(e.g. factor VIII in classical haemophilia), or occasionally
high concentrations of t-PA (e.g. produced by some
cancers) (Table 1).
Thrombosis can be viewed as a large, occlusive platelet-
fibrin haemostatic plug in a vein, artery, or within the
heart. It develops in veins as a result of venous trauma
(e.g. central venous catheters, intravenous pacemakers) or
venous stasis in leg veins (e.g. after major trauma, surgery
or medical illness; puerperium; long-distance travel).
In arteries, thrombosis usually occurs following rupture
of an atheromatous plaque, exposing blood to the
thrombogenic plaque contents.
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Antithrombotic drugs
Antiplatelet and anticoagulant drugs reduce formation
of the platelet and fibrin components of thrombi,
respectively. At the same time they reduce the platelet
or fibrin components of haemostatic plugs. Fibrinolytic
agents such as streptokinase or recombinant t-PA
(alteplase) lyse not only thrombi, but also haemostatic
plugs. Hence with all antithrombotic drugs, their thera-
peutic benefits (reduction of clinical morbidity and
mortality from thrombosis) must be balanced against
their adverse effects (especially, increased risk of bleeding)
[1–3] (Table 1).
Antiplatelet drugs
Aspirin is the most commonly used antiplatelet drug, and
has the largest evidence base in meta-analyses of
randomized controlled trials [4–6]. It reduces the risk of
both arterial [4] and venous [5] thromboembolic events
by about 25%, at the cost of a 75% increased risk of
bleeding. Because aspirin reduces prostaglandin synthesis
in the gastrointestinal tract as well as in platelets, its
adverse effects include nausea, dyspepsia, constipation
and bleeding. The absolute annual risk of excessive major
gastrointestinal bleeding is about 1 per 200 patients; the
absolute annual risk of intracranial haemorrhage is about
1 in 2000 patients [6]. While the risk- benefit equation is
therefore generally favourable for aspirin in secondary
prevention of arterial thrombosis in patients with clinical
arterial disease (annual risk about 5%), and in prophylaxis
of venous thromboembolism after major surgery (risk of
clinical DVT about 2% in first 35 days) [5], careful con-
sideration should be given to its use in primary prevention
of arterial thrombosis (risk: benefit favourable when
annual risk of myocardial infarction is 1.5–2%) [6, 7].
The thiopyridenes (ticlopidine, clopidogrel) are antag-
onists of the platelet ADP receptor. They are slightly more
effective than aspirin in secondary prevention of arterial
thrombosis [8], and do not increase the risk of dyspepsia
or gastrointestinal bleeding [9]. They are more expensive
than aspirin and therefore used mostly in patients in whom
aspirin is contra-indicated or not tolerated [1]. Clopidogrel
is preferred to ticlopidine because the latter may cause
neutropenia and requires initial monitoring of blood cell
counts. The combination of clopidogrel with aspirin is
more effective than aspirin alone in reducing thrombosis
within coronary stents [10] and in acute coronary
syndromes [11].
The IIb/IIIa platelet receptor blockers are also more
effective (when added to aspirin) than aspirin alone, when
given intravenously in acute coronary syndromes [4]. In
contrast, oral IIb/IIIa platelet receptor blockers were
not more effective than aspirin in secondary prevention of
arterial thrombosis, and increased the risks of bleeding,
thrombocytopenia and death [12].
Anticoagulants
Subcutaneous heparins (unfractionated or low molecular
weight) are effective at low doses in prophylaxis of
venous thromboembolism [2, 3] and at higher doses in
initial treatment of venous thromboembolism [3]. Low
molecular weight heparins are more expensive, but have
the advantages of once-daily administration (facilitating
out-patient prophylaxis or treatment) and possibly lower
risks of bleeding and of heparin associated thrombocyto-
penia. Low molecular weight heparins are more effective
than unfractionated heparin in acute coronary syndromes
[3]. Newer parenteral anticoagulants include hirudins and
pentasacharides [3].
Warfarin is the oral anticoagulant used most com-
monly, and is effective in secondary prevention of
venous thromboembolism as well as prevention of cardiac
thromboembolism in high-risk patients with atrial
fibrillation and/or heart valve disease or prostheses. Its
major disadvantages include high inter- and intraindividual
variability in effect (partly as a result of influences of diet,
drugs and alcohol), a narrow therapeutic range, and the
need for regular monitoring of the INR. The annual risk
of major bleeding is 1–5%. Newer oral anticoagulants
include antithrombins and factor Xa inhibitors, which
may have more predictable effects, and therefore may
not require monitoring and may have a lower risk of
bleeding [3].
Thrombolytics
Thrombolytics (streptokinase, t-PA) has an established
place in treatment of acute myocardial infarction [3].
Their use in acute stroke [13] and acute venous
thromboembolism [14, 15] remains controversial, because
of the uncertain balance of bleeding risk and benefit.
Table 1 Thrombosis is haemostasis in the wrong place.
Haemostasis Thrombosis
Vessel wall Small vessels – injury Veins – stasis
Arteries – rupture
Platelets Low count Antiplatelets
Low vWF
Coagulation Low VIII Anticoagulants
Fibrinolysis High t-PA Fibrinolytics
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Venous thromboembolism
Primary prophylaxis
Early studies of primary prophylaxis of venous thrombo-
embolism in high-risk surgical and medical groups of
hospitalized patients used mainly radiolabelled fibrinogen
leg scans, which are sensitive to deep vein thrombosis
(DVT) especially in the calf veins. In the 1980s such
screening was abandoned because of the potential risk
of viral transmission by human fibrinogen. Routine ven-
ography is invasive, but more specific and sensitive for
detection of DVT in proximal veins, which are common
after lower limb trauma and orthopaedic surgery. The
majority of such thrombi are asymptomatic, but a minority
cause symptomatic venous thromboembolism (DVT or
pulmonary embolism), in 1–5% of patients following
major trauma or major orthopaedic or general surgery,
in the absence of specific prophylaxis [2, 3]. The risk of
fatal PE is 0.1–1%. About 1–5% of such patients also
experience excessive bleeding (e.g. wound haematomas)
in the absence of specific prophylaxis.
Clinical endpoints in trials of primary prophylaxis
include asymptomatic DVT at routine venography (usually
performed 10–14 days after surgery/hospitalization, or
earlier if DVT is suspected clinically). The frequency of
asymptomatic DVT in the absence of specific prophylaxis
is about 40–50% after elective total hip or knee
replacement or hip fracture; and about 20–25% after
major general surgery or medical illness; about one-third
of thrombi are in proximal veins (popliteal or above) [2, 3].
Asymptomatic DVT has been the primary endpoint in
recent trials, because trials of several hundred patients
are powered to detect reductions in risk compared to the
comparator group. However, this endpoint has recently
been criticised especially by UK orthopaedic surgeons,
because only a minority of such patients experience
clinical events; and because if venography is performed
4–5 weeks after elective hip or knee replacement (and 2–3
weeks after heparin prophylaxis is stopped) the incidence
of DVT approaches 40% (i.e. heparin prophylaxis only
postpones DVT development) [2].
A recent meta-analysis of randomized controlled trials
of antiplatelet agents (usually aspirin) including the large
PEP trial, observed that aspirin reduced the risks of
asymptomatic DVT, symptomatic DVT, and clinical PE,
each by about one-third [5]. This benefit was not
outweighed by the increased risk of major bleeding
(about 1 in 1000 in the absence of concomitant heparin
prophylaxis). The large (17 000 patient) PEP trial did not
perform screening for DVT, and was designed to detect
reductions in clinical DVT and PE.
Pooled analyses of low-dose heparin or unfractionated
heparin prophylaxis indicate that they reduce the
incidence of asymptomatic DVT by about two-thirds
in general surgical and general medical patients, and
also reduce the incidence of PE by about 50% [2, 3].
A key question in orthopaedic surgery is whether or
not extended heparin prophylaxis (or warfarin in some
North American centres) is more beneficial than routine
prophylaxis with spinal/epidural anaesthesia, mechanical
prophylaxis (e.g. compression stockings) and aspirin for
5 weeks; given the increased risk of bleeding on heparin
or warfarin [2].
Treatment
Routine treatment of acute venous thromboembolism
(DVT or PE) is with heparin for a few days and warfarin
for 3–6 months. Endpoints in studies include recurrent
symptomatic DVT (confirmed by a new or extended
thrombus at ultrasound examination or venography)
or symptomatic PE (confirmed by a new or extended
thrombus/perfusion defect at isotope lung scan-
ning, spiral CT scanning, pulmonary angiography, or
echocardiography) [2, 3].
Arterial thromboembolism
In secondary prevention of arterial thrombosis, the usual
composite efficacy endpoint is myocardial infarction
(MI), stroke, or vascular death (e.g. in meta-analyses by
the Antiplatelet Trialists’ Collaboration, now the Anti-
thrombotic Trialists’ Collaboration) [4]. Vascular death
includes fatal MI, fatal stroke, sudden cardiac death, and
death resulting from other vascular occlusive events such
as mesenteric or limb infarction: all of these clinical events
usually have a thrombotic basis. New stable angina or
claudication is ‘vascular’, but not necessarily ‘thrombotic’:
for example it can occur following unusual exercise.
On the other hand, new unstable angina or critical limb
ischaemia requiring acute hospital admission is more
likely to be ‘thrombotic’. Coronary, peripheral or cerebral
arterial interventions (angiography, angioplasty, bypass
grafting, carotid endarterectomy) are certainly costly occur-
rences; however, there is wide international variation in
their incidences, resulting in uncertain generalisability of
these endpoints.
About 85% of strokes are thromboembolic (because
of cardiac, aortic, carotid or vertebrobasilar thrombo-
embolism; or lacunar infarction), while about 15% are
haemorrhagic. It is clearly desirable to try to establish
through early investigations whether strokes occurring
during trials of antithrombotic agents are thromboembolic
or haemorrhagic, for explanatory analysis and discussion.
However, to the patient a stroke is a stroke, hence it is
pragmatic to include all strokes in the primary composite
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endpoint, because the clinical effect of antithrombotic
drug administration is on the total stroke rate.
While the WHO definition of stroke has been used
for many years, it was recently suggested that the WHO
definition of myocardial infarction be replaced by a new
definition, based primarily on a serial rise and fall in
recently introduced sensitive measures of myocardial
necrosis (troponin or creatinine kinase MB fraction)
[16]. Such a finding should be accompanied by symptoms
of ischaemia, ECG Q-wave or ST segment elevation or
depression, or coronary intervention. Pathological find-
ings of acute or healed MI are also included. This pro-
posed redefinition has been criticised [17]. It moves from
a primarily clinical diagnosis, supported by investigations
(as for stroke and other vascular events), to a primarily
biochemical diagnosis, which requires patients to survive
long enough to be admitted to one of the minority of
hospitals in the world which performs such investigations
routinely, and to stay alive for sufficient days for the results
of their blood tests to go up and down (or for a coronary
intervention – as noted above, the wide international
variation in intervention rates makes such definitions
poorly generalisable). Because most patients with acute
MI die before hospital admission, are admitted to hospitals
which do not perform routine troponin or CK-MB assays,
or die before the results of such assays can go up and down;
and because autopsies are not routinely performed, it is
clear that only a minority of patients with MI will be
detected by the new definitions; while those with fatal
MI will be virtually ignored [17]. The new definition
will pick up many trivial cases of ‘troponin blips’ which
leads to inappropriate ‘labelling’, with adverse conse-
quences for patients. It is not a true consensus statement
applicable to epidemiological and healthcare monitoring
studies of MI and it is to be hoped that the WHO will
not approve it. It would be a dangerous precedent, for
‘new definitions’ of stroke and peripheral ischaemia could
also become defined primarily by blood measures of
release products from damaged organs, of doubtful clinical
significance.
Definitions of bleeding
Robust, clinically meaningful and truly consensual
definitions are required, not only for the thrombotic
events which antithrombotic drugs may prevent, but also
for the bleeding events which they may produce. This is
clearly important if practitioners are to use evidence from
trials and observational studies to judge the balance of risks
and benefits for their individual patients. Estimates such
as numbers needed to treat (NNT) and to harm (NHH)
require such definitions of thrombotic and bleeding
events.
Consensus is approaching that major bleeding includes:
’ Substantial fall in haemoglobin concentration
(i4 g dlx1) without other explanation
’ Need for hospital admission and/or blood/red cell
transfusion
’ Fatal or disabling bleeding (e.g. intracranial, intraspinal,
retroperitoneal, intraocular)
Can we predict thrombotic events?
At present, prediction of risk of arterial thrombotic events
(MI and other CHD events, and stroke) is calculated from
charts of equations using data on age, sex, and classical risk
factors including smoking, diabetes, arterial pressure, and
cholesterol (usually, ratio of total: HDL cholesterol) from
prospective studies such as Framingham [18]. Such charts
should be used to calculate absolute risk of CHD when
considering primary prophylaxis with aspirin [6, 7]. These
charts can also be used to illustrate (to patients as well as
healthcare professionals) the cardiovascular risk benefits
of reducing smoking, arterial pressure, and cholesterol
concentrations [18]. However, it remains a paradox that
we give smoking advice and/or drugs to smokers; blood
pressure advice and/or drugs to those with high blood
pressure; and cholesterol–lowering drugs to those with
high cholesterol; but we give antithrombotics without
measuring thrombotic tendency. It is therefore worth
assessing whether blood tests of thrombotic tendency are
useful in predicting groups of patients at high risk of
arterial thrombosis, over and above the risk predicted by
classical CHD risk predictors.
While several phenotypic or genetic tests have been
evaluated, to date meta-analyses of prospective studies
show that plasma fibrinogen [19], viscosity [20], von
Willebrand factor [21], t-PA antigen [22], and fibrin
D-dimer [23] are independent risk predictors for coronary
heart disease. There is some evidence that these variables
are also predictors of stroke, although further studies are
required. In particular, D-dimer (a global marker of
activation of coagulation forming cross-linked fibrin,
followed by endogenous fibrinolysis) may be of interest,
because high plasma levels can be reduced by warfarin but
not by aspirin [24]. In theory therefore, high D-dimer
concentrations in persons might predict subsets of the
population who might benefit more from longterm
anticoagulant prophylaxis, rather than longterm antiplate-
let prophylaxis. This hypothesis requires testing in
prospective studies.
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